Molecular targeting therapy using TKIs is currently one of the most successful forms of treatment in the clinic, and includes imatinib targeting BCR-ABL in chronic myeloid leukemia (CML) and gefitinib/erlotinib in EGFR-mutated LAD (3). This evidence concerns the gene EGFR and chronic myelogenous leukemia, BCR-ABL1 positive.